Park City, UT (PRWEB) June 18, 2013
NuView Life Sciences (NLS), a privately held company developing next generation imaging and in vitro diagnostic (IVD) biomarkers, today announced the results from a translational research study with NuView’s novel urine screen in development for the early detection of Prostate and Bladder Cancer. The study was presented in an oral presentation at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada on Sunday, June 9th. NLS acquired the exclusive commercialization rights to this technology from Thomas Jefferson University (TJU) earlier this year.
Mathew Thakur, PhD, Professor Radiology and Director of Radiopharmaceutical Research and Molecular Imaging at TJU and his colleagues, presented results from a translational study to detect the presence of minute quantities of tumor cells shed into urine by targeting the expression of the vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide (VPAC1) receptors. In this study, urine samples were collected from normal volunteers (n=23) and from 19 patients with Prostate Cancer (n=7), Bladder Cancer (n=2), benign hyperplasia (BPH) (n=1) and 9 with other symptoms. Utilizing TP4303, a VPAC1 specific biomolecule labeled with a near infrared fluorophore, the IVD identified shed tumor cells in the urine samples of all patients (100%) with Prostate or Bladder Cancer. Importantly, no shed tumor cells were detected in the urine samples of healthy volunteers or the patient with BPH.
“We are excited about the potential for this Prostate and Bladder Cancer urine screen because it addresses a huge unmet medical need,” said Paul Crowe, Chairman and CEO of NLS. “This could have a dramatic impact on how Prostate and Bladder Cancer are detected, which ultimately leads to improved patient outcomes.”
There remains a large unmet medical need for the accurate, non invasive, simple and reliable detection of Prostate and Bladder Cancer. Currently, routine screening of the general public for bladder cancer is not recommended by any major professional organization. This is due to lack of a sensitive and specific test that will detect bladder cancer in an individual without clinical symptoms of disease. Current screening for Prostate Cancer by digital rectal examination (DRE) and Prostate Specific Antigen (PSA) blood levels result in low cancer predictive ability and lead to increased numbers of potentially unnecessary invasive biopsy procedures.
Prostate cancer is the second leading cause of cancer death in American men and over 72,000 men and women are estimated to be diagnosed with Bladder Cancer in the U.S. in 2013. Mortality from Prostate and Bladder Cancer strongly correlates with the stage of disease upon diagnosis. Therefore, the ability to detect early-stage cancer before clinical presentation would have a dramatic effect upon patient outcomes.
About NuView’s VPAC1 Technology platform
Previous research by Dr. Thakur and others has revealed that Breast, Prostate, and other cancer cells express the VPAC1 oncogene product in high density on their cell surface. This expression occurs at a very early stage in oncogenic transformation, well before changes in cell morphology. For Prostate Cancer cells, VPAC1 expression occurs well before the elevation of Prostate Specific Antigen (PSA).
This VPAC1-based urine screen (TP4303) utilizes the same technology as NLS-VPAC1 ([Cu-64]-TP3805), our positron emission tomography (PET)-based molecular imaging diagnostic. Recently, Dr. Thakur presented results from a PET imaging study in Breast Cancer patients where NLS-VPAC1 unequivocally identified 100% (n=19) of the malignant lesions, irrespective of their hormonal status. NLS-VPAC1 also detected all (100%) sentinel lymph nodes (n=4). NuView is developing NLS-VPAC1 for the identification and localization of malignant Breast and Prostate tumors using PET and plans to initiate multi-center clinical trials in 2013.
About NuView Life Sciences
NuView Life Sciences is a privately held company whose mission is the development and commercialization of a new generation of molecular imaging diagnostic agents and disease-specific biomarkers. We are developing a vertically integrated, radiopharmaceutical manufacturing, and distribution organization to address current supply problems in the marketplace and facilitate development of our product pipeline.
For more information, please visit http://www.nuviewinfo.com.
Read the full story at http://www.prweb.com/releases/2013/6/prweb10828830.htm.
Copyright©2012 Vocus, Inc.
All rights reserved